feed,title,long_url,short_url
r/science:15+,[Cancer] Patients with locally advanced rectal cancer and tumors with deficient mismatch repair (dMMR) have shown a remarkable response to treatment with the programmed cell death-1 (PD-1) inhibitor dostarlimab (Jemperli),https://redd.it/v5hwxt,
